Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF01776 Ribosomal L22e protein family |
Function |
- |
Biological Process |
GO:0002181 cytoplasmic translation |
Molecular Function |
GO:0003735 structural constituent of ribosome |
Cellular Component |
GO:0005840 ribosome GO:0015934 large ribosomal subunit GO:0022625 cytosolic large ribosomal subunit GO:0022626 cytosolic ribosome GO:0044391 ribosomal subunit GO:0044445 cytosolic part |
KEGG |
hsa03010 Ribosome |
Reactome |
R-HSA-157279: 3' -UTR-mediated translational regulation R-HSA-72737: Cap-dependent Translation Initiation R-HSA-1643685: Disease R-HSA-156842: Eukaryotic Translation Elongation R-HSA-72613: Eukaryotic Translation Initiation R-HSA-72764: Eukaryotic Translation Termination R-HSA-72689: Formation of a pool of free 40S subunits R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit R-HSA-74160: Gene Expression R-HSA-5663205: Infectious disease R-HSA-168254: Influenza Infection R-HSA-168255: Influenza Life Cycle R-HSA-168273: Influenza Viral RNA Transcription and Replication R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives R-HSA-392499: Metabolism of proteins R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) R-HSA-927802: Nonsense-Mediated Decay (NMD) R-HSA-156902: Peptide chain elongation R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane R-HSA-2408522: Selenoamino acid metabolism R-HSA-2408557: Selenocysteine synthesis R-HSA-72766: Translation R-HSA-192823: Viral mRNA Translation R-HSA-72312: rRNA processing R-HSA-8868773: rRNA processing in the nucleus and cytosol |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between RPL22L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of RPL22L1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of RPL22L1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of RPL22L1 in various data sets.
|
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RPL22L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RPL22L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RPL22L1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RPL22L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of RPL22L1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | RPL22L1 |
Name | ribosomal protein L22-like 1 |
Aliases | 60S ribosomal protein L22-like 1 |
Chromosomal Location | 3q26.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between RPL22L1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |